Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Franklin, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Gallatin, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Gallatin, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Germantown, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Hermitage, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Hermitage, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Lebanon, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Lebanon, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Memphis, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Murfreesboro, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Nashville, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Smyrna, TN
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Smyrna, TN
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Bedford, TX
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Grapevine, TX
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Grapevine, TX
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Houston, TX
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Arlington, VA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Arlington, VA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Fairfax, VA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Gainesville, VA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Gainesville, VA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Leesburg, VA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Leesburg, VA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Winchester, VA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Winchester, VA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Woodbridge, VA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Woodbridge, VA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Vancouver, WA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Madison, WI
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
mi
from
Adelaide,
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
mi
from
Adelaide,
Click here to add this to my saved trials
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma
Status: Enrolling
Updated:  2/18/2016
University of Cincinnati
mi
from
Cincinnati, OH
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma
Status: Enrolling
Updated: 2/18/2016
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma
Status: Enrolling
Updated:  2/18/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma
Status: Enrolling
Updated: 2/18/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies
Status: Enrolling
Updated:  2/24/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies
Status: Enrolling
Updated: 2/24/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies
Status: Enrolling
Updated:  2/24/2016
NCKUH
mi
from
Tainan,
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies
Status: Enrolling
Updated: 2/24/2016
NCKUH
mi
from
Tainan,
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Honolulu, HI
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Louisville, KY
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Jackson, MS
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Austin, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Anniston, AL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Birmingham, AL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bentonville, AR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bentonville, AR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Jonesboro, AR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Paragould, AR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Paragould, AR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bakerfield, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bakerfield, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bell Gardens, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bell Gardens, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Huntington Beach, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Long Beach, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Roseville, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Roseville, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Sacramento, CA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Colorado Springs, CO
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Washington,
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Atlantis, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Bay Pines, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Ft. Lauderdale, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Miami, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Pensacola, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
St. Petersburg, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Vero Beach, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Vero Beach, FL
Click here to add this to my saved trials